{"filing":{"accession_number":"0001104659-26-068659","cik":"0001649989","ticker":"OTLK","company_name":"Outlook Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"tm2616461d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm"},"events":[{"id":7710,"run_id":6774,"accession_number":"0001104659-26-068659","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"summary":"The Company resubmitted a Biologics License Application (BLA) for ONS-5010 to the FDA on June 1, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead candidate, as BLA resubmission represents progress toward potential commercialization and would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation), so it is classified as other_material.","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-06-01","form":"8-K","submitted_at":null,"items":[{"id":3016,"accession_number":"0001104659-26-068659","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company resubmitted a Biologics License Application (BLA) for ONS-5010 to the FDA on June 1, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead candidate, as BLA resubmission represents progress toward potential commercialization and would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:35.673273+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3016,"accession_number":"0001104659-26-068659","item_number":"8.01","item_title":null,"event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The Company resubmitted a Biologics License Application (BLA) for ONS-5010 to the FDA on June 1, 2026. This is a material regulatory milestone for a biopharmaceutical company's lead candidate, as BLA resubmission represents progress toward potential commercialization and would affect investor assessment of the company's pipeline and prospects. However, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M\u0026A, impairment, or litigation), so it is classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:15:35.673273+00:00","company_name":"Outlook Therapeutics, Inc.","ticker":"OTLK","filing_date":"2026-06-01"}]}